EGFR and breast carcinoma: The main signaling pathways enriched by KEGG included gastric cancer, breast cancer, proteoglycans in cancer, EGFR tyrosine kinase inhibitor resistance, endocrine resistance, hepatocellular carcinoma, MAPK signaling pathway, and hepatitis B.